Alzheimer’s disease and inherited neurodegeneration
The sponsor’s clinical research centers on Dominantly Inherited Alzheimer Disease (DIAD) and related forms of early-onset Alzheimer’s disease caused by genetic mutations, with attention to disease onset, progression, and clinical impairment.
- Dominantly inherited Alzheimer disease
- Early-onset Alzheimer’s disease
- Genetic mutation–associated dementia risk
Active studies include participants who are at risk for, or living with, inherited Alzheimer’s disease across multiple collaborating sites.
Amyloid and beta-amyloid pathology
Research activity is focused on therapies aimed at reducing amyloid burden and limiting Aβ accumulation, with interest in how amyloid removal influences disease onset and downstream disease expression.
- Amyloid removal
- Aβ accumulation
- Anti-amyloid treatment
The trial portfolio includes evaluation of amyloid-targeted approaches in individuals carrying mutations linked to DIAD.
Biomarkers of Alzheimer’s disease progression
The sponsor supports research on disease-related biomarkers associated with Alzheimer’s pathology, including markers used to track progression and downstream effects of treatment in genetically defined populations.
- Biomarker change
- Downstream Alzheimer’s biomarkers
- Disease progression markers
These studies examine how treatment relates to measurable biological changes alongside clinical outcomes.
Cognitive and clinical impairment
Clinical interest extends to the slowing or prevention of cognitive decline and clinical progression in people with inherited Alzheimer’s disease, with emphasis on preserving function in the earliest stages of disease.
- Cognitive impairment
- Clinical progression
- Dementia prevention
Recruiting studies are examining whether treatment can delay deterioration in individuals with a known Alzheimer’s disease-causing mutation.
